Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial

Table 3 Treatment-related adverse events

Treatment-related adverse events	Any grade	Grade 1	Grade 2	Grade 3
All adverse events, n (%)	22 (88)	17 (68)	14 (56)	3 (12)
Decreased lymphocyte count	14 (56)	7 (28)	7 (28)	0
Increased GGT	7 (28)	3 (12)	3 (12)	1 (4)
Decreased platelet count	5 (20)	0	4 (16)	1 (4)
Increased blood bilirubin	5 (20)	4 (16)	1 (4)	0
Rash	4 (16)	2 (8)	2 (8)	0
Increased ALT	2 (8)	1 (4)	1 (4)	0
Increased AST	2 (8)	2 (8)	0	0
Myositis	2 (8)	0	1 (4)	1 (4)
Abnormal liver function	2 (8)	1 (4)	1 (4)	0
Paronychia	2 (8)	2 (8)	0	0
Jaundice	2 (8)	0	2 (8)	0
Decreased white blood cell count	1 (4)	1 (4)	0	0
Decreased neutrophil count	1 (4)	1 (4)	0	0
Ascites	1 (4)	0	1 (4)	0
Arthritis	1 (4)	0	1 (4)	0
Pneumonia	1 (4)	0	1 (4)	0
Myocarditis	1 (4)	1 (4)	0	0
Dry eye	1 (4)	1 (4)	0	0

GGT: Gamma-glutamyl transpeptidase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.